

CHOICE STUDENTS, FACULTY, & ALUMNI

WHERE TO FIND US AT ISPOR 2023

Impacting Innovation, Value, and Healthcare Decision Making

MAY 7-10, 2023

Boston, Massachusetts

<https://www.ispor.org/>

All times listed are EDT

SUNDAY, MAY 7th, 2023

8:00 AM – 12:00 PM: SHORT COURSE MORNING SESSION

005: A Health Economics Approach to US Value Assessment Frameworks

Faculty: **Louis P. Garrison, PhD**, University of Washington, Charles Phelps, MBA, PhD, University of Rochester; Richard Willke, PhD, ISOPR.

1:00 PM – 5:00 PM: SHORT COURSE AFTERNOON SESSION

003: Core Concepts and Approaches to Early-Stage Health Technology Assessment

Faculty: **Lotte Steuten, PhD**, Office of Health Economics; **William Canestaro, PhD, MSc**, Washington Research Foundation; **Erik Landaas, PhD, MPH**, W. L. Gore & Associates, Inc., Flagstaff.

004: Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products

Faculty: **Louis P. Garrison, PhD**, University of Washington; Adrian Towse, MA, MPhil, Office of Health Economics; **Josh Carlson, MPH, PhD**, University of Washington.

MONDAY, MAY 8th, 2023

10:15 AM – 11:15 AM: BREAKOUT SESSION 1

104: RWE and Health Disparities in HTAs: Is Transferability the Main Barrier for Equity Data Sharing Across Borders?

Location: Room 104A-C, Level 1

Moderator: **Blythe Adamson, PhD, MPH**, Flatiron Health

Panelists: Evie Merinopoulou, MSc, Cytel Inc.; Grammati Sarri, PhD, MSc, DiDS, ; Joshua Ray, MSc, Global Access, F. Hoffmann-La Roche.

10:15 AM – 11:15 AM: PODIUM SESSION 1

109: Health Equity in HEOR

Location: Theater 2, Poster and Exhibit Hall, Exhibit Level

P8: Bias in, Bias out? Implications of Using Real-World Data with Differentially Measured Outcomes to Generate Prediction Models When Race Is a Predictor

Presenting Author: **Sara Khor, CHOICE PhD Student**

Presentation Time: 10:15 AM – 10:30 AM

11:45 AM - 12:45 AM: ISPOR FORUMS

115: Generalized Cost Effectiveness Analysis – From Theory to Practice

Location: Room 205C, Level 2

Discussants: **Jon Campbell, PhD**, Institute for Clinical and Economic Review; **Lou Garrison, PhD** CHOICE Institute, School of Pharmacy; Chris Leibman, PharmD, MS, Value, Access, Public Policy and, Government Affairs; Patricia Synnott, MS, MALD, Tufts Medical Center

Moderator: Noam Kirson, PhD, Analysis Group, Inc.

1:45 PM – 2:45 PM: BREAKOUT SESSION 2

130: Patient-Centric Preference Assessment on Treatment-Process Attributes: Challenges and Opportunities

Location: Room 210C, Level 2

Discussants: Elizabeth Clearfield, MHS, Institute for Policy Advancement; Lizheng Shi, PhD, MA, MsPharm Tulane University School of Public Health and Tropical Medicine; Melanie Whittington, PhD, MS, Institute for Clinical and Economic Review.

Discussion Leader: **Lou Garrison, PhD**, CHOICE Institute, School of Pharmacy, University of Washington

1:45 PM – 2:45 PM: SPOTLIGHT SESSION

124: Medicare Drug Price Negotiation in the US: Implications, Evidence Needs, and Unanswered Questions

Location: Room 210A-B, Level 2

Panelists: **Jens Grueger, PhD**, Boston Consulting Group; **Jan E. Hansen, PhD**, Genentech; Kristina Martin, MPA, Center for Medicare and Medicaid Services.

Moderator: **Sean Sullivan, BScPharm, PhD**, CHOICE Institute, School of Pharmacy, University of Washington

2:45 PM – 3:30 PM: STUDENT AND NEW PROFESSIONAL RECEPTION

Career Catalyst Reception: Health Policy and Pharmacoeconomics

Location: Connection Zone, Northwest Lobby, Level 2

Moderator: Julie Patterson, PharmD, PhD, Senior Director, National Pharmaceutical Council

Speakers: Inma Hernandez, PharmD, PhD, Associate Professor, Division of Clinical Pharmacy, UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences; John Michael O'Brien, PharmD, MPH, President and CEO, National Pharmaceutical Council; **Sean D. Sullivan, BScPharm, PhD**, Professor, The CHOICE Institute, School of Pharmacy, University of Washington

3:15 PM - 4:15 PM: ISPOR FORUMS

137: Considerations for Conducting Exploratory, Descriptive, and Other Non-HETE Studies Using Real-World Data - Balancing Quality, Purpose, and Resources

Location: Room 204A-B, Level 2

Moderator: Eric Barrette, PhD, Medtronic

Speakers: **Rafael Alfonso-Cristancho, MD, PhD**, Value Evidence Outcomes, GSK; Ami Buikema, MPH, EDA, Optum Global Solutions, Eden Prairie; William Crown, PhD, The Heller School for Social Policy and Management, Brandeis University

138: What Is an Open-Source Model? Forging a Path to Definition

Location: Room 205C, Level 2

Moderator: Stephanie Harvard, PhD, The University of British Columbia

Speakers: Koen Degeling, PhD, Lumen Value & Access, Hengelo, OV; Eric Jutkowitz, PhD, Brown University; **Blythe Adamson, PhD, MPH**, Flatiron Health.

4:45 PM – 5:45 PM: BREAKOUT SESSION 3

150: In Search of a Goldilocks Reference Case in the US: Could an Insured Member or Patient-Informed Reference Case Be 'Just Right?'

Location: Room 205C, Level 2

Moderator: Barry Liden, Juris Doctor (JD), USC Schaeffer Center

Panelists: **Jon Campbell, PhD**, Institute for Clinical and Economic Review,; **Julia F. Slejko, PhD**, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy; Elisabeth Oehrlein, PhD, MS, Applied Patient Experience, LLC.

152: Considering the Impact of the Inflation Reduction Act on Drug Development and Patients

Location: Room 210A-B, Level 2

Moderator: **Lotte Steuten, PhD**, Office of Health Economics

Panelists: Ravi Mehrotra, PhD, 5point0; Michael Ward, MS, Alliance for Aging Research; Jason Spangler, MD, MPH, FACPM, Innovation and Value Initiative

4:45 PM – 5:45 PM: Member Group Meeting

New Special Interest Groups in Development Open Meeting: Global Access to Medical Innovation/Environmental Sustainability in HEOR

Location: Room 107A, Level 1

Presenter: **Lou Garrison, PhD**, CHOICE Institute, School of Pharmacy, University of Washington

MONDAY POSTER PRESENTATIONS

9:45 AM – 1:15 PM: POSTER SESSION 1

Location: Poster and Exhibit Hall, Exhibit Level
Presentation Time: 12:15 PM – 1:15 PM

Zach Baldwin, CHOICE/AbbVie Postdoctoral Fellow

EPH31: [Incidence of Malignancies in Sickle Cell Disease: A Systematic Review](#)

Poster Board #31

STA: Genetic, Regenerative & Curative Therapies

Yilin Chen, CHOICE PhD Student

RWD19: [Comparative Effectiveness Using External Controls for Single-Arm Trials of Pembrolizumab in Tumor-Agnostic Indications Leveraging Real-World Data](#)

Poster Board #19

Clinical Outcomes; Study Approaches; Comparative Effectiveness or Efficacy

Spencer Cheng, CHOICE/Genentech Postdoctoral Fellow

SA5: [Defining Colorectal Cancer Recurrence with Structured-Health Data Algorithms: A Targeted Literature Review](#)

Poster Board #5

Study Approaches

Arvind Katta, CHOICE/ Bayer Postdoctoral Fellow

EE47: [Cost-Effectiveness of Abiraterone, Enzalutamide, and Apalutamide in Metastatic Castration-Sensitive Prostate Cancer \(MCSPC\): A Partitioned-Survival Model](#)

Poster Board # 47

Clinical Outcome; Economic Evaluation; Comparative Effectiveness or Efficacy; Cost-comparison; Effectiveness; Utility; Benefit Analysis

Hyunwoo Kim, CHOICE/ Neurocrine Biosciences Postdoctoral Fellow

EE34: [Cost-Effectiveness Analysis of Valbenazine Compared with Deutetrabenazine for the Management of Huntington Chorea](#)

Poster Board #34

Economic Evaluation; Methodological & Statistical Research; Study Approaches; Cost-comparison; Effectiveness; Utility; Benefit Analysis

Katherine Necas, UW PharmD Student

HPR31: [Value-Based Purchasing Arrangements in Medicaid Programs: Targeted Review](#)

Poster Board #530

Health Policy & Regulatory; Risk-sharing Approaches

3:15 PM – 6:45 PM: POSTER SESSION 2

Location: Poster and Exhibit Hall, Exhibit Level

Presentation Time: 5:45 PM – 6:45 PM

Tori Dayer, CHOICE PhD Student

EE183: [Cost-Effectiveness Model for PTAH Oral Immunotherapy in Peanut Allergy Using Two-Year Extension Trial Data](#)

Poster Board #183

Economic Evaluation; Cost-comparison; Effectiveness; Utility; Benefit Analysis

Yun Joo (Karris) Jeon, CHOICE PhD Student

EE175: [Cost-Effectiveness of Onasemnogene in Pre-Symptomatic Newborns with a Diagnosis of Spinal Muscular Atrophy and Two Copies of Survival Motor Neuron 2 Gene](#)

Poster Board # 175

Economic Evaluation; Cost-comparison; Effectiveness; Utility; Benefit Analysis

Jae Kim, CHOICE/AbbVie Postdoctoral Fellow

EE109: [Cost Effectiveness of Dual Vs. Triple Therapy in Management of Atrial Fibrillation with Percutaneous Coronary Intervention](#)

Poster Board #109

Economic Evaluation; Cost-comparison; Effectiveness; Utility; Benefit Analysis

Qixin Li, CHOICE/Bayer Postdoctoral Fellow

CO84: [Real-World Assessment of All-Cause and Cardiovascular-Related Inpatient Readmissions, Healthcare Resource Utilization, and Costs Among Type 2 Diabetes Patients with and without Chronic Kidney Disease](#)

Poster Board #136

Clinical Outcomes; Economic Evaluation; Study Approaches; Clinical Outcomes Assessment.

Greg Guzauskas, CHOICE Research Scientist

EE140: [The Long-Term Costs and Health Impacts of Huntington's Disease: A Novel Health Economic Modeling Framework](#)

Poster Board #239

Clinical Outcomes; Economic Evaluation; Methodological & Statistical Research; Clinical Outcomes Assessment

5:30 PM – 7:30 PM: UW-CHOICE ALUMNI & FRIENDS RECEPTION

Location: [Lord Hobo Seaport](#), 2 Drydock Ave, Boston, MA 02210

TUESDAY, MAY 9th, 2023

8:30 AM – 9:45 AM: PLENARY SESSION

200: Second Plenary Session- AI Wants to Chat With You: Accept or Ignore?

Location: Ballroom East-West, Level 3

Co-Moderators: **Blythe Adamson, PhD**, MPH, Flatiron Health; **Mitchell Higashi, PhD**, GeneDx; Sontag D, Massachusetts Institute of Technology (MIT); Cecchi G, IBM Research; Ritchey MB, FDA, CDRH; Shreibati J, Google Health; Mary Beth Ritchey, PhD, FDA.

10:15 AM – 11:15 AM: BREAKOUT SESSION 4

205: Beyond Burden of Illness – Using RWE for Advanced HEOR Analytics

Location: Room 205A-B, Level 2

Discussants: **Blythe Adamson, PhD**, MPH, Flatiron Health; **Jon Campbell, PhD**, Institute for Clinical and Economic Review; Stephanie Manson, PhD, Novartis, East Hanover.

Discussion Leader: **Anirban Basu, PhD, MS**, CHOICE Institute, School of Pharmacy, University of Washington

11:30 AM - 12:15 PM: Poster Session 3 Poster Tour

Location: Poster Tour Area A
211 Oncology Poster Tour

Ifechukwu (Ben) Nwogu, CHOICE PhD Student

EE261: [Cost-Effectiveness of Adding Darolutamide to Docetaxel and Androgen Deprivation Therapy in the Treatment of Metastatic Hormone-Sensitive Prostate Cancer](#)

Poster Board # 2A

Economic Evaluation, Methodological & Statistical Research, Study Approaches

11:45 AM - 12:45 PM: ISPOR FORUMS

215: Assessing Real-World Data From Electronic Health Records (EHRs) for HTA

Location: Room 204A-B, Level 2

Discussants: **Blythe Adamson, PhD**, MPH, Flatiron Health; Rachael Fleurence, PhD, National Institutes of Health; Seamus Kent, PhD, Flatiron Health

Moderator: **Scott Ramsey, MD, PhD**, CHOICE Institute, School of Pharmacy, University of Washington

217: Using HEOR Methods for Improving the Implementation of Value-Based Healthcare

Location: Room 206A-B, Level 2

Discussants: **Lotte Steuten, PhD**, Office of Health Economics; William Vincent Padula, PhD, MSc, MS, Department of Pharmaceutical and Health Economics, USC School of Pharmacy; Ana Paula Beck da Silva Etges, PhD, Eng., Avant-garde Health

Moderator: **Jens Grueger, PhD**, Boston Consulting Group, Freiburg, BW, Germany

1:45 PM – 2:45 PM: BREAKOUT SESSION 5

225: Disentangling the Complex Landscape of Infectious Diseases: How Can Modelers Best Choose the Level of Complexity that Increases Both Investment in Technologies and Model Interpretability?

Location: Room 204A-B, Level 2

Discussants: Martin Meltzer, PhD, Health Economics and Modeling Unit, Center for Disease Control and Prevention; Pedro Nascimento de Lima, PhD, Rand Corporation, Santa Monica; **Mindy Cheng, PhD**, Vir Biotechnology.

Moderator: Anuj Mubayi, PhD, IQVIA

1:45 PM - 2:45 PM: ISPOR NEW PROFESSIONALS SESSION

231: Things They Didn't Teach You in Grad School

Moderator: Anna Hung, PharmD, PhD, Duke University School of Medicine.

Speaker: Sanket Shah, MBBS, PhD, Novo Nordisk, Inc. & **Blythe Adamson, PhD**, MPH, Flatiron Health.

3:15 PM - 4:15 PM: EDUCATIONAL SYMPOSIA

242: Driving Changes in Obesity Care: A Multi-Stakeholder Perspective on the Value of Non-Invasive Interventions

Location: Room 210A-B

Moderator: **Sean Sullivan, BScPharm, PhD**, CHOICE Institute, School of Pharmacy, University of Washington

3:15 PM - 4:15 PM: ISPOR FORUMS

238: Underestimated: Identifying and Addressing Mechanisms of Bias in HEOR (An ISPOR Women in HEOR Forum)

Location: Room 206A-B, Level 2

Discussants: **Julia F. Slejko, PhD**, Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy; **Davene Wright, PhD**, Harvard Pilgrim Health Care Institute and Harvard Medical School; Serena Jingchuan Guo, MD, PhD, University of Florida College of Pharmacy,

Moderator: **Shelby Reed, PhD**, RPh, Duke University School of Medicine, Duke Clinical Research Institute

4:45 PM – 5:45 PM: PODIUM SESSION 6

253: Health Policy and Pricing

Location: Theater 1, Poster and Exhibit Hall, Exhibit Level

P42: Value-Based Pricing for Drugs with Accelerated Approval Incorporating Uncertainty and Risk Aversion

Presenting Author: **Boshen Jiao, PhD Program Alumni**

Presentation Time: 5:30 PM – 5:25 PM

TUESDAY POSTER PRESENTATIONS

9:45 AM – 1:15 PM: POSTER SESSION 3

Location: Poster and Exhibit Hall, Exhibit Level

Presentation Time: 12:15 PM – 1:15 PM

Shiven Bhardwaj, CHOICE PhD Student

EE256: [Comparative Cost-Utility Analysis of Galcanezumab and Fremanezumab for Migraine Prevention in Individuals with Chronic Migraine Who Have Tried 2 to 4 Prior Preventive Treatments](#)

Poster Board # 256

Clinical Outcomes; Study Approaches; Economic Evaluation; Comparative Effectiveness or Efficacy; Cost-comparison; Effectiveness; Utility; Benefit Analysis

Emily Callen, CHOICE PhD Student

EE264: [Immunotherapy for Advanced and Recurrent dMMR Endometrial Cancer: A Cost-Effectiveness Analysis](#)

Poster Board # 264

Economic Evaluation; Study Approaches; Effectiveness ; Cost-comparison; Effectiveness; Utility; Benefit Analysis

Zizi Elsi, CHOICE PhD Student

EE284: [Exploring the Value of a Novel Health Technology Tool to Support Diagnosis of Autism Spectrum Disorder](#)

Poster Board # 284

Economic Evaluation; Medical Technologies; Cost-comparison; Effectiveness; Utility; Benefit Analysis; Medical Devices

Louis P. Garrison, The CHOICE Institute

HSD65: [From the Triple Aim to the Quintuple Aim to the ISPOR Value Flower: Are Health Systems Prepared for High-Value Cell and Gene Therapies?](#)

Poster Board # 65

Health Policy & Regulatory; Risk-sharing Approaches

Kevin H. Li, UW PharmD Student

EE246: [Cognitive Behavioral Therapy \(CBT\) Vs. Oral Antidepressants for Treatment of Depression in Older Adults: A Cost-Effectiveness Analysis](#)

Poster Board # 226

Economic Evaluation; Cost-comparison; Effectiveness; Utility; Benefit Analysis.

Felipe Montano-Campos, CHOICE PhD Student

OP11: [The Influence of Extracurricular Activities on Radiology Resident Selection Decisions](#)

Poster Board # 717

Organizational Practices, Patient-Centered Research

Ifechukwu (Ben) Nwogu, CHOICE PhD Student

EE261: [Cost-Effectiveness of Adding Darolutamide to Docetaxel and Androgen Deprivation Therapy in the Treatment of Metastatic Hormone-Sensitive Prostate Cancer](#)

Poster Board # 2A

Economic Evaluation, Methodological & Statistical Research, Study Approaches

Patricia J. Rodriguez, PHD Program Alumni

CO99: [Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin As First-Line Therapy in Type 2 Diabetes](#)

Poster Board # 108

Clinical Outcomes; Real World Data & Information Systems; Comparative Effectiveness or Efficacy,

Ashley Tabah, CHOICE PhD Student

HPR81: [Effect of Medicare Eligibility at Age 65 Years on Prescription of High-Risk Medications in Individuals with Multiple Chronic Conditions](#)

Poster Board # 81

Health Policy & Regulatory; Study Approaches; Insurance Systems & National Health Care; Surveys & Expert Panels

Bella Vo, UW PharmD Student

EE257: [Cost Effectiveness Analysis of Qulipta in Episodic Migraine Prophylaxis](#)

Poster Board # 226

Economic Evaluation; Cost-comparison; Effectiveness; Utility; Benefit Analysis.

3:15 PM – 6:45 PM: POSTER SESSION 4

Location: Poster and Exhibit Hall, Exhibit Level

Presentation Time: 5:45 PM – 6:45 PM

Ron Dickerson, CHOICE PhD Student

EPH212: [Drug Prices and Crime: An Empirical Study Examining Northern Central America](#)

Poster Board # 212

Economic Evaluation; Health Technology Assessment; Methodological & Statistical Research

Julia Fox, CHOICE PhD Student

EE369: [Soothing the Soul: Cost-Effectiveness Evaluation of Group Music Therapy in Reducing Clinically-Significant Agitation Among People with Dementia](#)

Poster Board #369

Economic Evaluation; Cost-comparison; Effectiveness; Utility; Benefit Analysis.

Stella Ko, CHOICE/ Genentech Postdoctoral Fellow

PCR186: [Health State Utility and Quality of Life Measures for Neovascular Age-Related Macular Degeneration](#)

Poster Board # 808

Health State Utilities, Instrument Development, Validation, & Translation, Patient-reported Outcomes & Quality of Life Outcomes

Enrique Saldarriaga, CHOICE PhD Program Alumni

PCR158: [Preferences for Online Pre-Exposure Prophylaxis Delivery Among Potential Clients in Kenya: A Discrete Choice Experiment](#)

Poster Board # 158

Patient-Centered Research; Patient Behavior and Incentives; Stated Preference & Patient Satisfaction.

Kangho Suh, PhD Program Alumni

CO153: [Examining Time to All-Cause Hospitalization or Death Among Second-Generation Antipsychotics Long-Acting Injectables in Schizophrenia](#)

Poster Board #116

Clinical Outcomes, Comparative Effectiveness or Efficacy

Rachel Wittenauer, CHOICE PhD Student

EE444: [Cost of Childhood Rsv Management and Cost-Effectiveness of Rsv Interventions in Low- and Middle-Income Countries: A Systematic Review](#)

Poster Board #444

Economic Evaluation; Study Approaches; Study Approaches; Effectiveness; Utility; Benefit Analysis; Literature Review & Synthesis

WEDNESDAY, MAY 10th, 2023

8:45 AM – 9:45 AM: PODIUM SESSION 7

306: PROs and Patient Experiences in Oncology and Rare Diseases

Location: Theater 2, Poster and Exhibit Hall, Exhibit Level

P50: Using Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Chronic Myeloid Leukemia Patients Who Are in Remission

Presenting Author: **Felipe Montano-Campos, CHOICE PhD Student**

Presentation Time: 9:30 AM – 9:45 AM

WEDNESDAY POSTER PRESENTATIONS

8:30 AM – 11:30 AM: POSTER SESSION 5

Location: Poster and Exhibit Hall, Exhibit Level

Presentation Time: 9:00 AM – 10:00 AM

Mark Bounthavong, PhD Program Alumni

EE482: [Public, Private, and Out-of-Pocket Spending Comparisons between Opioid and Non-Opioid Users, 2008-2019](#)

Poster Board # 241

Economic Evaluation; Study Approaches; Surveys & Expert Panels

Ron Dickerson, CHOICE PhD Student

HTA83: [Investigating the Net Benefit of a Clinical Algorithm Detecting Chemotherapy Patients' Risk of Emergency Care and Inpatient Hospitalization](#)

Poster Board # 83

Health Policy & Regulatory; Methodological & Statistical Research

Zizi Elsi, CHOICE PhD Student

HTA96: [Applying Early Health Technology Assessments to Inform Novel Health Technology Innovation](#)

Poster Board # 96

Economic Evaluation; Health Technology Assessment; Study Approaches; Cost-comparison; Effectiveness; Utility; Benefit Analysis.

Louis P. Garrison, The CHOICE Institute

EE553: [Estimating the Economic Burden of Progressive Multifocal Leukoencephalopathy in the United States: A Literature Review and Assessment](#)

Poster Board # 53

Clinical Outcomes; Economic Evaluation; Clinical Outcomes Assessment; Cost-comparison; Effectiveness; Utility; Benefit Analysis

Joyce Jiang, CHOICE PhD Student

EE510: [Economic Modeling of Adjuvant or Neoadjuvant Therapies in Oncology – HTA Review of NICE Technology Appraisals, 2019-2022](#)

Poster Board # 510

Economic Evaluation; Study Approaches; Cost-comparison; Effectiveness; Utility; Benefit Analysis.

Stella Ko, CHOICE/ Genentech Postdoctoral Fellow

EE543: [The Impact of Different Utility Values on a Cost-Effectiveness Model in Diabetic Macular Edema](#)

Poster Board # 543

Economic Evaluation; Patient-Centered Research; Study Approaches; Cost-comparison; Effectiveness; Utility; Benefit Analysis.

Thomas Majda, CHOICE/Genentech Postdoctoral Fellow

EE459: [Racial Health Disparities in Acute Ischemic Stroke: A Targeted Literature Review for Estimates to be Used in Distributional Cost-Effectiveness Analysis](#)

Poster Board # 220

Economic Evaluation; Study Approaches; Clinical Outcomes, Comparative Effectiveness or Efficacy

Jacinda Tran, CHOICE PhD Student

PCR208: [Patient Preferences for Long-Acting Antiretroviral Therapy Among Patients Living with HIV in Kenya: Results from a Pilot Discrete Choice Experiment](#)

Poster Board # 724

Patient-Centered Research, Study Approaches

Kangho Suh, PhD Program Alumni

CO212: [The Potential Long-Term Comparative Effectiveness of Larotrectinib Vs. Immune Checkpoint Inhibitors for Treatment of Metastatic NTRK Gene Fusion-Positive Cancers](#)

Poster Board # 125

Clinical Outcomes, Comparative Effectiveness or Efficacy

David Veenstra, CHOICE Faculty

EE512: [Potential Long-Term Benefits of Extended Adjuvant Neratinib in Patients with High-Risk Hormone Receptor Positive \(HR+\) HER2+ Early-Stage Breast Cancer \(ESBC\) Following Use of T-DM1 or Pertuzumab: A Population Effectiveness Model](#)

Poster Board #309

Economic Evaluation; Study Approaches; Decision Modeling & Simulation